• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Commissioner Warns of Shutdown’s Impact on Clinical Trials

FDA Commissioner Warns of Shutdown’s Impact on Clinical Trials

January 14, 2019
William Myers

As the partial government shutdown entered a record-setting fourth week, FDA Commissioner Scott Gottlieb said it was no longer “business as usual” at the agency — calling the shutdown “one of the most significant operational challenges in FDA’s recent history.”

Over the past few weeks, Gottlieb has announced multiple shifts from normal at the FDA, including that new INDs sent to the FDA won’t be considered “accepted” while the shutdown continues. Normally, INDs are considered automatically approved if the FDA doesn’t respond within 30 days. The FDA announcement stops the legal clock.

And he’s indicated that drug user fee money has been reallocated to postmarket drug safety efforts. The FDA is currently able to use carryover user fee funding from fiscal 2018 to support ongoing reviews, but Gottlieb has estimated a prolonged shutdown will exhaust the available funds, beginning with the PDUFA program, which currently has about three weeks of funding remaining.

“With no indication of a resolution to the shutdown in sight, it is likely that the effects on clinical trials and drug development programs will continue to multiply,” WCG Clinical Chief Medical Officer Lindsay McNair said last week.

“Sponsors are unsure whether they should proceed with planned screening and dosing dates at research centers; limited space at research centers may be booked far in advance, so forgoing the currently scheduled dates may mean that it takes months to get the study rescheduled,” she added.

The bigger drug sponsors seem to be in better shape at the moment than smaller companies. Spokeswomen for Novartis and GlaxoSmithKline each said that their companies’ trials haven’t yet been affected by the shutdown.

Smaller companies aren’t so sure. Biopharma company Aimmune said last week that its marketing application for a peanut allergy treatment had been thrown into limbo.

Deprived of his usual media relations team, Gottlieb has been communicating with the trials industry through his Twitter account.

When the mother of a child with a rare neurological disease said that her child’s trials had been delayed by the shutdown, Gottlieb tweeted, “Nobody should be unable to access a clinical trial or compassionate use drug owing to the funding lapse. We will help her. Our drug review staff remains at their posts across our centers.”

Since 1980, there have been at least nine government shutdowns and since the mid-1990s, they’ve grown increasingly protracted. There were two in 2018. Whether or not they directly affect trials, they’re creating a long-term uncertainty, says Michael A. Swit, a lawyer who concentrates his practice on FDA regulation.

“The lesson is, if you’re concerned about shutdowns impacting your process, make sure you get everything done in the middle of a budget cycle,” he says. “Frankly, look at everything that FDA does — the danger to the public health by the public shutdown is inexcusable.”

President Trump and Congress will take up the government funding issue again this week.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing